BOZE’s founding family earned its assets from the pharmaceutical industry. With the long-term, stable, and responsible investment philosophy, BOZE family office combines the characteristics of pharmaceutical with diversified industry strategies, sets its sights on long-term value, and takes investment in optimal sub-funds as the core strategy. BOZE has managed to cover core sectors such as technology, innovation, and emerging consumption while retaining the characteristics of pharmaceutical.

BOZE pharmaceutical team has more than 20 years of work experience in healthcare and has abundant resources in the industry. The expert team shares a unique perspective of the pharmaceutical industry and distinguishes fund managers with professional barriers, profound understanding, and excellent performance in the pharmaceutical sector, which makes pharmaceutical investment a feature of BOZE asset allocation. BOZE focuses on the long-term, global, diverse and premium asset allocation, explore investment in non-medical industry, focuses on core sectors such as technology, innovation, and emerging consumption. BOZE selects the best global fund managers from thousands of selected global private equity funds and now has established long-term collaboration with domestic and international elite fund managers from Goldman Sachs, Morgan Stanley, CICC, CDH Investments and Blackstone.

BOZE strictly monitors each link of fund selection, due diligence investigation, and risk control, organizes managers, projects, project stages, and industries in a diversified manner, and appoints the best managers for each field to minimize risks of time, industries, and each stage. BOZE investment currencies include RMB and USD. Geographically, BOZE investment spans China, the United States, Asia, and Europe, keeping a close watch on DPI and IRR performance indicators to achieve and maintain long-term, stable returns.